The SMART study was the first to demonstrate that mortality in this setting is linked to HIV replication, inflammatory markers such as IL-6 and soluble CD14 (sCD14), and coagulation markers such as D-dimers [ 23].
There was also evidence of interaction in the WHII (Pinteraction = 0.004), but not the SMART Study (Pinteraction = 0.34) or the NBS (Pinteraction = 0.79).
The Eat Smart study aims to contribute to the knowledge base of effective dietary strategies for the clinical management of the obese adolescent and examine the cardiometablic effects of a reduced carbohydrate diet versus a low fat diet.
Recently, as follow-up on the SALT trial, the same authors published the SMART study results [25, 27].
In the Strategies for Management of Antiretroviral Therapy (SMART) study, increased levels of the pro-inflammatory cytokine interleukin 6 (IL-6) and of D-dimer, a marker of fibrinolysis, predicted all-cause mortality in persons with treated HIV infection, and impaired liver function among hepatitis co-infected patients [7], [8].
A recent analysis on the SMART study found an association between CRP, IL-6 and d-dimer and the risk of CVD events [ 34].
10 11 However, in view of a potential risk due to LABA monotherapy, highlighted by the SMART study, 12 and by systematic reviews 4 including a meta-analysis conducted by the US Food and Drug Administration FDAA), 13 it has been proposed that studies should be conducted that specifically assess this risk with currently available and novel LABA/ICS products.
Previous results from the SMART study showed that HIV/viral hepatitis co-infected persons with impaired liver function are at increased risk of death following interruption of antiretroviral therapy (ART).
In brief, the association between ABC and risk of MI was also found in a Danish cohort study [ 4] and in the SMART study dataset [ 7].
The SMART study is an ongoing prospective single-centre cohort study in patients with manifest arterial disease or cardiovascular risk factors [ 20].
